Warning: There are an increasing number of fraudulent websites that impersonate ECCMID. We would like to alert all our members and delegates to possible scams and we strongly advise you to use only the official ECCMID online registration for your bookings.
Abstract Categories 1a. HIV/AIDS (incl. diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance) 1b. Viral hepatitis (incl. diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance) 1c. Influenza and respiratory viruses (incl. diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility / resistance) 1d. Herpesviruses (incl. diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts) 1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (all aspects) 1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV) 1g. Viral epidemiology – general, prevalence studies, molecular and genomic epidemiology (other than respiratory viruses, herpesviruses, hepatitis & HIV) 1h. Antiviral drugs, treatment, susceptibility/resistance (other than respiratory viruses, herpesviruses, hepatitis & HIV) 1i. Basic and applied virology (incl. in vitro and in vivo models, novel methods) 2a. Tuberculosis and other mycobacterial infections (incl. epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention) 2b. Severe sepsis, bacteraemia & endocarditis (incl. epidemiology, diagnosis, host bio-markers, treatment and outcome prediction) 2c. Community-acquired respiratory infections (incl. epidemiology, clinical, imaging, treatment & prevention) 2d. Community-acquired abdominal/gastrointestinal, urinary tract & genital infections (incl. epidemiology, clinical, imaging, treatment & prevention) 2e. Community acquired skin, soft tissue, bone & joint infections ((incl. epidemiology, clinical, imaging, treatment & prevention, excl prostheses) 2f. Community acquired nervous system and other multi-system bacterial infections (incl. epidemiology, clinical, imaging, treatment & prevention) 2g. Zoonotic bacterial infections (incl. foodborne, waterborne and vector-borne pathogens, veterinary microbiology and One Health aspects, excl AMR) 2h. Other intracellular or rare bacteria 3a. Resistance surveillance & epidemiology: MRSA, VRE & other Gram-positives 3b. Resistance surveillance & epidemiology: Gram-negatives 3c. Susceptibility testing methods (incl. assay validation, phenotypic assays and comparative studies, excl TB) 3d. Resistance mechanisms incl. in vitro and in vivo studies, mobile elements (excl TB) 3e. Resistance detection / prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods) 3f. Clinical outcome of resistant infections (retrospective and prospective studies, excl clinical trials of new drugs) 3g. Spread of resistance incl. carriage, reservoirs, ecology, models (excl nosocomial transmission) 3h. Policy aspects of AMR incl. societal impact, economics, mitigation 4a. Diagnostic bacteriology (incl. culture based, traditional and general microbiology, serology) 4b. Laboratory management (incl. automation, data management, QC/QA, regulatory aspects) 4c. MALDI-TOF and other proteomic methods 4d. Molecular diagnostics (incl. POCT and syndromic testing) 4e. Strain typing and surveillance (incl. molecular, genomic and other advanced methods) 4f. Whole genome sequencing (incl. pathogen characterisation, diagnostics, excl typing) 4g. Microbiome studies (incl. clinical and diagnostic studies, One Health aspects) 4h. Clinical metagenomics 4i. Bioinformatics tools & pipelines 4j. Other novel diagnostic technologies 5a. Mechanisms of action, new compounds, preclinical data & basic pharmacology of antibacterial agents (incl. investigational and non-traditional therapeutics) 5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring 5c. New or repurposed antibacterial agents: clinical studies and trials 5d. Antimicrobial stewardship and prescribing (incl. interventions, monitoring, impact, decision-support / prediction tools, behavioural aspects) 5e. Safety, hypersensitivity and adverse effects of treatment 5f. Pharmacoepidemiology / pharmacoeconomics (incl. cost-effectiveness, modelling, data tools) 6a. Fungal disease epidemiology 6b. Diagnostic mycology (incl. traditional, molecular and other methods) 6c. Antifungal susceptibility testing &resistance (incl. surveillance) 6d. Antifungal drugs & treatment (incl. clinical trials) 6e. Basic mycology (incl. in vitro and in vivo studies, pathogenesis) 7a. Parasitic disease epidemiology 7b. Diagnostic parasitology (incl. traditional, molecular and other methods) 7c. Antiparasitic susceptibility & drug resistance (incl. surveillance) 7d. Antiparasitic drugs & treatment (incl. clinical trials) 7e. Travel medicine, migrant and refugee health 7f. Food & water safety, environmental health, vector epidemiology 7g. Global health, public health, health security and biosafety 7h. Infections in low-resource settings (incl. epidemiology, burden, health infrastructure, health disparities and vulnerable populations) 8a. Intravascular catheter-related infections 8b. Other foreign-body and implant-associated infections (incl. PJI) 8c. Surgical site infections 8d. Healthcare-associated pneumonia (incl. VAP) 8e. Hospital epidemiology, transmission, surveillance & screening (incl.. environment) 8f. Other healthcare associated infections (incl. CDI, hospital outbreaks) 8g. Infection control interventions and trials (incl.. microbiota transplantation) 8h. Disinfection & biocides 8i. Healthcare workers and infection prevention (incl. vaccination, behavioural aspects, training and practices) 9a. Microbial pathogenesis & virulence 9b. Host-pathogen interaction (incl. basic microbiome studies, animal models) 9c. Preclinical biofilm studies 9d. Experimental and cellular microbiology 9e. Basic science studies using Omics (in vitro and in vivo) 10a. Host genetics: infection susceptibility & primary immunodeficiency 10b. Infections in immunocompromised hosts (incl. epidemiology, clinical features and diagnosis, treatment , excl fungal infections) 10c. General vaccinology (incl..in vitro and in vivo studies, policy, social aspects) 10d. Antiviral vaccines (excl influenza, respiratory and bloodborne viruses and COVID-19) 10e. Antibacterial vaccines 10f. Other preventive modalities (incl. new vaccine technologies, antibody-based treatments) 10g. Immune response to infection (incl. in vitro, animal and human studies, laboratory assessment of immunity and response, excl sepsis biomarkers) 11a. Professional affairs and career development 11b. Publishing, ethics, other academic affairs 11c. Medical education for CM/ID 11d. Digital health and infection (incl. AI, data mining, informatics) 11e. Diversity and equality 11f. Advocacy and role of patients 12a. Basic science and virology 12b. Epidemiology - local, regional, national, global 12c. Clinical features, case management, complications, outcome (incl. long-term) 12d. Diagnostics (incl. molecular, genomic, rapid tests) 12e. Drug development and treatment modalities (incl. in vitro, animal, clinical trials, resistance) 12f. Immune response and modulation (incl. immunity and response measurement, immunomodulation, antibody treatment) 12g. Vaccine development, trials, efficacy, policy 12h. Infection prevention and control (incl. healthcare facilities, community, schools) 12i. Public health policy and mitigation (non-pharmaceutical interventions) 12j. Preparedness and response (COVID and future pandemics) 12k. Other societal aspects (incl.. economics, mental health) 12l. Virus evolution, variant detection and analysis, impact 13a. Viral infections 13b. Bacterial infections 13c. Fungal infections 13d. Parasitic infections 13e. Other unusual clinical situations
